Date: 2015-09-28
Type of information: Initiation of the trial
phase:
Announcement:
Company: Torii Pharmaceutical (Japan)
Product: house dust mite SLIT-tablet/Miticure™
Action
mechanism: sublingual allergy immunotherapy tablet
Disease: house dust mite allergy
Therapeutic area: Allergic diseases - Immunological diseases - Respiratory diseases
Country: Japan
Trial details:
Latest
news: * On September 28, 2015, Torii Pharmaceutical announced that it is initiating a new clinical Phase III trial to investigate the safety and efficacy of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet Miticure™ in paediatric patients (five-11 years). The trial is expected to enrol approximately 400 subjects.
